Trevena (NASDAQ:TRVN) Issues Earnings Results

Trevena (NASDAQ:TRVN) released its earnings results on Thursday. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter, reports. The business had revenue of $0.28 million during the quarter.

Trevena Stock Down 4.3 %

Shares of TRVN stock traded down $0.09 during mid-day trading on Friday, reaching $1.88. The stock had a trading volume of 12,705 shares, compared to its average volume of 7,046. The firm’s 50 day simple moving average is $3.27 and its 200 day simple moving average is $5.89. Trevena has a one year low of $1.13 and a one year high of $19.23. The firm has a market cap of $1.62 million, a PE ratio of -0.04 and a beta of 1.08.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Trevena in a report on Sunday, November 3rd. They issued a “sell” rating on the stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.